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Context 
Childhood cancer survivors experience chronic health conditions that impact health related 
quality of life (HRQOL) and participation in optimal physical activity.  
Objective 
The study aimed to determine independent effects of endocrine and metabolic disorders on 
HRQOL and physical activity.  
Design, Setting, and Patients 
Retrospective cohort with longitudinal follow-up of survivors of childhood cancer enrolled in the 
North American Childhood Cancer Survivor Study. 
Main Outcome Measures 
Medical Outcomes Short Form-36 estimated HRQOL while participation in physical activity was 
dichotomized as meeting or not meeting recommendations from the Center for Disease Control 
and Prevention. Log binomial regression evaluated the association of each endocrine/metabolic 
disorder with HRQOL scales and physical activity. 
Results 
Of 7,287 survivors, median age 32 years (18-54) at their last follow-up survey, 4,884 (67%) 
reported one or more endocrine/metabolic disorders. Survivors with either disorder were 
significantly more likely to be male, older, received radiation treatment, and experience other 
chronic health conditions. After controlling for covariates, survivors with any 
endocrine/metabolic disorder were more likely to report poor physical function risk ratio ([RR] 
1.25; 95% confidence interval [CI] 1.05-1.48), increased bodily pain (RR 1.27; CI 1.12-1.44), 
poor general health (RR 1.49; CI 1.32-1.68) and lower vitality (RR 1.21; CI 1.09-1.34) compared 
to survivors without. The likelihood of meeting recommended physical activity was lower 
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among survivors with growth disorders (RR 0.90; CI=0.83-0.97), osteoporosis (RR 0.87; 
CI=0.76-0.99), and overweight/obesity (RR 0.92; CI 0.88-0.96).  
Conclusion 
Endocrine and metabolic disorders are independently associated with poor HRQOL and sub-
optimal physical activity among childhood cancer survivors.  
Chronic endocrine and metabolic conditions adversely affected health-related quality of life and physical 
activity among adult survivors of childhood cancers followed in a large North American cohort. 
Introduction 
Significant improvements in the treatment of childhood cancer have led to a 5-year overall 
survival of >80%, leaving over 420,000 survivors alive in the United States1,2 at risk for early 
onset of cancer or therapy related chronic health conditions. Survivors are also at risk for poor 
health-related quality of life (HRQOL)3, and are less likely than peers to meet recommended 
guidelines for physical activity4,5.  Previous research has identified cranial radiation exposure as 
a risk factor for reduced HRQOL, and less than optimal participation in physical activity5.  
However, not all survivors with this exposure experience these adverse outcomes.  Given that 
exposures among adult survivors of childhood cancer who have lived for years after treatment 
are remote to both perceived quality of life and health behaviors, examination of the impact of 
potentially treatable organ-specific chronic health conditions on these outcomes is warranted;  
however, research in this area is limited6-9.  
Endocrine and metabolic disorders are among the most common chronic health conditions 
experienced by survivors, 10,11, 12-22 and often one condition contributes to additional conditions 
across the endocrine system. For example, growth hormone deficiency is associated with obesity, 
and sex-hormone deficiency with low bone mineral density. In the Childhood Cancer Survivor 
Study (CCSS), approximately 40-50% of survivors reported at least one endocrine disorder, a 
rate significantly higher compared with siblings22.   In that study and other work from the CCSS, 
metabolic conditions such as obesity and overweight were grouped together with other 
endocrinopathies. Endocrine and metabolic disorders have been associated with lower levels of 
physical activity and difficulties managing self-care and activities of daily living 6,9,23. However, 
the individual contribution of specific endocrinopathies or overweight/obesity on HRQOL and 
physical activity are unknown. Consequently, the primary aim of this study was to investigate the 
independent effects of the most common endocrine disorders and overweight/obesity on HRQOL 
and physical activity and, as a secondary aim, to examine if treatment of these disorders 
improved these outcomes.  
Subjects and Methods 
Participants 
The CCSS is a retrospective cohort study with longitudinal follow-up of adult survivors of 
childhood cancer.  The study design and cohort characteristics have been previously described in 
detail 10,24. Briefly, eligible participants were five-year survivors of leukemia, brain tumors, 
Hodgkin lymphoma, non-Hodgkin lymphoma, Wilms tumor, neuroblastoma, soft tissue sarcoma, 
or a malignant bone tumor diagnosed prior to age 21 years at one of 26 institutions across the 
United States and Canada between 1970 and 1986. These analyses included survivors who 
completed the baseline survey (administered in the mid-1990s) and two follow-up surveys 
(beginning in 2003 and 2007, respectively), and who were 18 years or older at the time of the 
2003 survey.  
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Outcome Measures 
The Medical Outcomes Short Form (SF-36) embedded in the 2003 survey was used to measure 
HRQOL25. Participants answered a 36-item questionnaire about their general health, well-being 
and quality of life over the previous 4-weeks. The SF-36 has two summary scales (physical and 
mental components) and eight individual subscales (physical function, role physical, bodily pain, 
general health, vitality, role emotional, social function, mental health). Each scale is presented as 
a T-score with a general population mean of 50 (standard deviation [SD] =10). Lower scores 
indicate worse HRQOL. Poor HRQOL was defined as a T-score of 40 or less3,25. Physical 
activity levels were determined based on self-reported frequency, duration and intensity of 
moderate and/or vigorous physical activity including participation in an organized activity over 
the previous four weeks26. Survivors who reported participating in recent organized physical 
activity were considered to have an active lifestyle. Survivors who met the equivalent of 150 
minutes of moderate activity per week were classified as meeting the Center for Disease Control 
and Prevention’s (CDC)  guidelines4. 
Independent Variables 
Survivors reported the presence of the following categories of endocrinopathies (grades 1-4 per 
the common terminology of adverse events CTCAE-version 4.03)10,27: thyroid disorders 
(hypothyroidism, hyperthyroidism, thyroid cancer, and thyroid nodules), growth disorders (short 
stature, growth hormone deficiency), gonadal dysfunction, osteoporosis, diabetes mellitus, 
overweight/obesity, and other endocrine disorders as previously described22. They also reported 
on current height (cm) and body weight (kg) from which body mass index (BMI; kg/m2) was 
calculated. Overweight was defined as BMI of 25 kg/m2 or greater but < 30 kg/m2 or a BMI at or 
above the 85th but less than 95th percentile per age and sex for participants younger than 18 years 
and obesity was defined as a BMI > 30 kg/m2 or BMI higher than 95th percentile per age and sex 
for participants younger than 18 years. Two follow-up questionnaires were used to ascertain the 
presence of endocrine/metabolic disorders and if survivors were being treated for the condition 
from the time of study entry until last follow-up. Responses to both surveys were used to define 
the endocrine condition because the first survey only recorded medications used to treat hormone 
deficiencies as a proxy for endocrine conditions, whereas the subsequent survey specifically 
asked survivors to report each endocrinopathy, and the year of onset of that condition, regardless 
of whether they were receiving treatment or not. Only survivors where the onset of endocrine 
conditions and replacement therapy for that condition occurred prior to the outcome measures 
were included in the analyses.  
Psychological measures of anxiety, depression and somatization were assessed using the 
Brief Symptom Inventory-18 (BSI-18), an 18- item scale that was embedded in the 2003 survey 
with a T score ≥ 63 indicating emotional distress within the preceding 7 days 28. Task efficiency, 
a neurocognitive construct related to initiating and completing tasks in a rapid manner and 
associated with lower physical activity, was measured by the CCSS neurocognitive questionnaire 
(CCSS-NCQ) 29, a self-reported measure in the 2003 survey. Both were used as adjustment 
variables when analyzing the physical activity outcomes. 
Statistical Analysis 
Demographic and treatment characteristics were compared between survivors with and without 
self-reported endocrine and metabolic disorders using chi-squared tests for categorical variables 
and t-test for continuous variables. We repeated this analysis with the exclusion of 
overweight/obesity as an outcome so that it focused only on endocrinopathies. Log binomial 
regression was used to evaluate the association of having any endocrine/metabolic disorder, as 
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well as the association of each individual endocrine/metabolic disorder with HRQOL and 
physical activity, followed by similar analyses after excluding overweight/obesity. Specific 
endocrine disorder therapy (replacement therapy for hypothyroidism, testosterone therapy, and 
hormone replacement therapy (HRT) for gonadal dysfunction among females), and the total 
number of endocrine disorders with the probability of a poor score (40 or lower) for each 
component of HRQOL, and each of the two measures of physical activity were analyzed using 
log binomial regression. All models were adjusted for sex, race, education, marital status, 
household income, health insurance, employment status, radiation therapy, amputation, and 
grade 3-4 (severe or life threatening or disabling) chronic health conditions other than endocrine 
disorders. The analysis of physical activity outcome was also adjusted for emotional distress and 
task-efficiency 28,30. 
Results 
Characteristics of study population  
Of the 7,287 survivors who completed the baseline and follow-up surveys and were 18 years or 
older at the time of the last follow-up survey, 4,884 (67%) had one or more endocrine or 
metabolic disorder. Survivors with these disorders were more likely than those without to be 
male, older at cancer diagnosis and at the time of each survey, and less likely to be employed. 
They were also more likely to have other grade 3-4 chronic health conditions as well as poor 
emotional health, and more likely to have received any radiation treatment compared to those 
without these conditions (Table 1). 
Characteristics of endocrine and metabolic disorders  
The most common condition was overweight/obesity, which was present in 50.7% of survivors 
(Table 2). Thyroid disorders were the most common endocrinopathy (22.9%), followed by 
growth disorders (19%). Females were more likely to report gonadal dysfunction than males.  
Relationship between type and number of endocrine and metabolic disorders and HRQOL  
Survivors with female gonadal dysfunction relative risk (RR=1.26, 95% confidence interval [CI] 
=1.08-1.46), osteoporosis (RR=1.45, 95% CI=1.29-1.63), diabetes mellitus (RR=1.23, 95% 
CI=1.08-1.40) or overweight/obesity (RR=1.25, 95% CI=1.12-1.38) had an elevated risk of a 
poor physical component summary score on the SF-36. Thyroid disorders (RR=1.16, 95% 
CI=1.01-1.34) and male gonadal dysfunction (RR=1.67, 95% CI=1.25-2.24) were associated 
with an elevated risk of a poor mental component summary score. The association between 
additional specific endocrinopathies and poor scores on the sub-scales of the SF-36 are displayed 
in Table 3.  
Survivors with greater than two endocrine/metabolic disorders had an elevated risk of poor 
physical component summary scores of HRQOL compared to those without a disorder (RR=1.7, 
95% CI=1.3-2.4). In addition, these survivors had a higher risk of limitations in performing 
physical activities (RR=1.8, 95% CI=1.2-2.7) showing lower scores in physical functioning, 
increased bodily pain, poor general health, and lower vitality compared to those without any 
endocrine disorder. Details of the number of endocrine disorders including overweight/obesity 
and poor scores on the subscales of SF-36 are shown in Table 4.  
Relationship between the types and numbers of endocrine and metabolic disorders and physical 
activity 
As shown in Table 5, participation in recent physical activity consistent with an active lifestyle 
was lower among those with growth disorders (RR=0.95, 95% CI=0.91-0.99) or diabetes 
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mellitus (RR=0.84, 95% CI=0.74-0.96) compared to those without these endocrine disorders. 
The likelihood of meeting the CDC guidelines for physical activity was lower among survivors 
who had a growth disorder (RR=0.90, 95% CI=0.83-0.97), osteoporosis (RR=0.87, 95% 
CI=0.76-0.99), or overweight/obesity (RR=0.92, 95% CI=0.88-0.96). Table 6 demonstrates that 
self-reported participation in recent physical activity was less likely among those with more than 
two endocrine/metabolic disorders compared to those with none (RR=0.90, 95% CI=0.83-0.97) 
or one (RR=0.92, 95% CI=0.85-0.99). Similarly, survivors with increasing number of 
endocrine/metabolic disorders were less likely to report meeting the CDC guidelines for physical 
activity compared to those without these disorders.  Those with greater than two endocrine or 
metabolic disorders were less likely to meet CDC physical activity recommendations compared 
to two (RR=0.84, 95% CI=0.73-0.96) or fewer (RR=0.82, 95% CI=0.72-0.94). 
We did not find any major differences in clinical characteristics, HRQOL sub-scales or 
physical activity between survivors with and without endocrine disorders after exclusion of 
overweight/obesity (see supplemental data, available at datadryad.org).  
Treatment effect and HRQOL outcomes 
As shown in Table 7, among survivors with hypothyroidism who reported use of thyroid 
hormone replacement, there was a significant lower risk of general mental health morbidities 
(RR=0.58, 95% CI=0.36-0.93) compared to those not reporting thyroid hormone replacement. 
Male survivors with gonadal dysfunction who reported use of testosterone had a lower risk for 
poor physical (RR=0.19, 95% CI=0.04-0.88), role limitations due to emotional problems 
(RR=0.38, 95% CI=0.15-0.98), social functioning (RR=0.22, 95% CI=0.05-0.97), and poor 
mental health (RR=0.22, 95%CI=0.06-0.86) compared to those who did not report taking 
testosterone replacement. 
Discussion 
In this study of over 7,000 survivors, we demonstrated an independent association of endocrine 
and metabolic disorders and reduced HRQOL and physical activity, even after adjusting for 
factors known to negatively influence these outcomes such as other chronic health conditions, 
cranial radiation therapy, and neuro-cognitive deficits. Two-thirds of survivors had at least one 
endocrine or metabolic disorder. These disorders significantly affected both the physical and 
mental components of HRQOL and were associated with reduced physical activity. In a previous 
study, an amputation or cranial radiation5 significantly affected HRQOL and physical activity.  
However, we demonstrated that even when adjusting for these treatment variables, 
endocrine/metabolic disorders have an incremental negative impact on HRQOL and physical 
activity suggesting that these disorders may be associated with pathophysiological changes that 
decrease HRQOL.  
Compared to survivors without any endocrine or metabolic disorders, a majority of survivors 
with these disorders reported significant limitations in physical functioning that included 
difficulties with activities of daily living, pain that limited their physical well-being, and a 
perception that their general health was poor. They also experienced symptoms of fatigue. The 
endocrine system integrates a complex set of physical and psychological signals that influence a 
variety of body systems, allowing an individual to adapt to their environment. While it was 
previously known that survivors with endocrine disorders are at risk for physical limitations, this 
analysis elucidated the impact of individual endocrinopathies. For example, survivors with 
thyroid disorders reported significant limitations in work and activities of daily living due to their 
physical health, were more likely to feel weak and tired at all times and perceived their general 
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health as poor and likely to get worse. While these survivors did not have increased symptoms of 
anxiety and depression, they did report that emotional problems interfered with their work or 
daily activities. Similar findings were observed in a Swiss study of childhood cancer survivors in 
which thyroid disorders were shown to impact all elements of HRQOL6. Impairments in HRQOL 
have been reported in adult, non-cancer populations with thyroid disorders 31-34. Given the 
critical role played by thyroid hormones in growth, development, and energy metabolism, and 
the long latency of developing thyroid disorders after cancer treatment, these finding support the 
need to remain vigilant for signs or symptoms of thyroid dysfunction in at-risk patients 
throughout the survivorship trajectory. This is particularly important because survivors who 
reported taking thyroid hormone replacement showed better overall mental health, an important 
aspect of HRQOL. 
We observed that male survivors with gonadal dysfunction reported more problems at work 
and performing physical activities of daily living due to poor physical health, more somatic pain, 
and a general feeling of being fatigued and worn out. Similar to previous reports of males with 
gonadal dysfunction 35 36,37, these members of our cohort experienced greater functional 
impairment due to emotional problems, interference in social activities due to these problems, 
and an increase in symptoms of anxiety and depression. Testosterone deficiency may have 
limited physical development, such as low muscle mass, and sexual health and function, such as 
poor libido and infertility. Encouragingly, survivors who reported taking testosterone 
replacement reported higher physical, social functioning, and mental health on the SF-36 than 
those not receiving replacement. Female survivors with gonadal dysfunction reported limitations 
in performing physical activities and increased body pain and feelings of poor physical health, 
which may be related to poor bone health due to estrogen deficiency 38,39.  
Survivors with diabetes mellitus and overweight/obesity, also reported impairment in 
physical activity, increased and functionally limiting pain, increased feelings of fatigue and 
decreased perception of general health and well-being without a significant impact on mental 
health. Careful and targeted counselling for weight reduction and other lifestyle changes are 
needed so that improvement in HRQOL can be achieved in these survivors.  
The negative impact of endocrine and metabolic disorders on physical domain subscales of 
the HRQOL was first reported by Ness at al 9. Our study is the first to show that among survivors 
with endocrine disorders, those with growth and bone disorders were less likely to report 
adherence to the CDC physical activity guidelines. These disorders if untreated affect lean 
muscle mass, muscle and bone strength and may lead to poor exercise tolerance23. In addition, 
survivors with growth disorders also reported an inactive lifestyle. This is significant as it is well 
known that subjects with growth hormone deficiency are at risk for poor cardiovascular 
outcomes40. Survivors with diabetes mellitus and those who were overweight/obese also reported 
poor compliance with CDC guidelines. Targeting exercise interventions to this group could 
produce significant health benefits that may potentially alter the underlying disease trajectories 
of diabetes and obesity. Our results also showed that it was harder to maintain physical activity 
with cumulative effects of more than one endocrine/metabolic disorder. These results should 
prompt exercise interventions for survivors with multiple endocrinopathies. 
 There are several limitations to this study. First, the diagnosis of endocrine and metabolic 
disorders was obtained from a self-reported survey. This might underestimate the proportion of 
survivors with these disorders in our study as previous studies have shown that screening and 
risk-based assessment frequently detects endocrine disorders that survivors are not aware of 41,42.  
The physical activity outcome in this study was a self-reported measure and were not be 
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validated against known objective measurements like resting energy expenditures or 
accelerometers. Due to the study-design, we were not able to determine if survivors were 
receiving optimum treatment or were compliant with medications prescribed to treat an 
endocrinopathy and so cannot determine if poorer HRQOL and lower physical activity was 
associated with having an untreated endocrinopathy, or if even adequately treated 
endocrinopathies negatively influence these outcomes. However, we observed better outcomes in 
many aspects of the HRQOL among those survivors reporting taking thyroid and male sex 
hormones compared to those who were not on these replacement medications. Further 
investigations are required in the setting of a prospective study design to confirm and validate 
these findings.  
In summary, childhood cancer survivors with endocrine and metabolic disorders are more 
likely to have functional impairment, decreased physical activity, and an inactive lifestyle. This 
study provides the first evidence of how each of the more common endocrine and metabolic 
disorders affects HRQOL and physical activity. Prospective studies designed to evaluate the 
treatment interventions of these disorders on HRQOL and physical activity are needed to 
optimize improvement in these outcomes. 
National Cancer Institute, CA55727, Gregory T Armstrong; St.Jude Children's Hospital 
Cancer Center Core Grant, CA21765, Not Applicable 
Acknowledgements:  
This work was supported by the National Cancer Institute (CA55727, G.T. Armstrong, Principal 
Investigator). Support to St. Jude Children’s Research Hospital also provided by the Cancer 
Center Support (CORE) grant (CA21765, C. Roberts, Principal Investigator).  
Corresponding Author Contact Information:  Kamnesh Pradhan. MD, MS, Address: 
Riley Hospital for Children, Indiana University School of Medicine, 705, Riley Hospital 
Drive, Indianapolis, IN 46202, USA., Phone Number: 317-944-8784, Email Address: 
pkamnesh@iu.edu 
Reprint Requests: Kamnesh Pradhan. MD, MS, Address: Riley Hospital for Children, 
Indiana University School of Medicine, 705, Riley Hospital Drive, Indianapolis, IN 
46202, USA. 
Disclosure Summary:  
KRP is employed by Eli Lilly and Company. The other authors have nothing to disclose. 
DATA AVAILABILITY: 
All data generated or analyzed during this study are included in this published article or in the 
data repositories listed in References. 
References 
1. Surveillance, Epidemiology, and End Results Program Cancer Statistics Review (CSR). 
1975-2015; https://seer.cancer.gov/csr/1975_2015/browse_csr. Accessed January 3rd, 2019. 
2. Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long risks 
and responsibilities. Nat Rev Cancer. 2014;14(1):61-70. 
3. Zeltzer LK, Lu Q, Leisenring W, Tsao JC, Recklitis C, Armstrong G, Mertens AC, 
Robison LL, Ness KK. Psychosocial outcomes and health-related quality of life in adult 
childhood cancer survivors: a report from the childhood cancer survivor study. Cancer 
Epidemiol Biomarkers Prev. 2008;17(2):435-446. 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00627/5528895 by IU
PU
I U
niversity Library user on 06 August 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00627 
 
 
8
4. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger 
W, Heath GW, King AC, et al. Physical activity and public health. A recommendation from the 
Centers for Disease Control and Prevention and the American College of Sports Medicine. 
JAMA. 1995;273(5):402-407. 
5. Ness KK, Leisenring WM, Huang S, Hudson MM, Gurney JG, Whelan K, Hobbie WL, 
Armstrong GT, Robison LL, Oeffinger KC. Predictors of inactive lifestyle among adult survivors 
of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 
2009;115(9):1984-1994. 
6. Rueegg CS, Gianinazzi ME, Rischewski J, Beck Popovic M, von der Weid NX, Michel 
G, Kuehni CE. Health-related quality of life in survivors of childhood cancer: the role of chronic 
health problems. J Cancer Surviv. 2013;7(4):511-522. 
7. Kadan-Lottick NS, Dinu I, Wasilewski-Masker K, Kaste S, Meacham LR, Mahajan A, 
Stovall M, Yasui Y, Robison LL, Sklar CA. Osteonecrosis in adult survivors of childhood 
cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2008;26(18):3038-3045. 
8. Ness KK, Baker KS, Dengel DR, Youngren N, Sibley S, Mertens AC, Gurney JG. Body 
composition, muscle strength deficits and mobility limitations in adult survivors of childhood 
acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;49(7):975-981. 
9. Ness KK, Hudson MM, Ginsberg JP, Nagarajan R, Kaste SC, Marina N, Whitton J, 
Robison LL, Gurney JG. Physical performance limitations in the Childhood Cancer Survivor 
Study cohort. J Clin Oncol. 2009;27(14):2382-2389. 
10. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, 
Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison 
LL. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 
2006;355(15):1572-1582. 
11. Gibson TM, Mostoufi-Moab S, Stratton KL, Leisenring WM, Barnea D, Chow EJ, 
Donaldson SS, Howell RM, Hudson MM, Mahajan A, Nathan PC, Ness KK, Sklar CA, 
Tonorezos ES, Weldon CB, Wells EM, Yasui Y, Armstrong GT, Robison LL, Oeffinger KC. 
Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer 
diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 
2018. 
12. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA. 
Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the 
Childhood Cancer Survivor Study. J Pediatr. 2007;150(4):370-375, 375 e371. 
13. Chow EJ, Liu W, Srivastava K, Leisenring WM, Hayashi RJ, Sklar CA, Stovall M, 
Robison LL, Baker KS. Differential effects of radiotherapy on growth and endocrine function 
among acute leukemia survivors: A childhood cancer survivor study report. Pediatr Blood 
Cancer. 2013;60(1):110-115. 
14. Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, 
Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Tarbell NJ, Sallan SE, Cohen LE. Height and 
weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J 
Clin Oncol. 2003;21(15):2953-2960. 
15. Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumours and 
radiotherapy. Pituitary. 2005;8(3-4):203-211. 
16. Gurney JG, Kadan-Lottick NS, Packer RJ, Neglia JP, Sklar CA, Punyko JA, Stovall M, 
Yasui Y, Nicholson HS, Wolden S, McNeil DE, Mertens AC, Robison LL. Endocrine and 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00627/5528895 by IU
PU
I U
niversity Library user on 06 August 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00627 
 
 
9
cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer 
Survivor Study. Cancer. 2003;97(3):663-673. 
17. Loeffler JS, Tarbell NJ, Garber JR, Mauch P. The development of Graves' disease 
following radiation therapy in Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1988;14(1):175-
178. 
18. Meacham LR, Gurney JG, Mertens AC, Ness KK, Sklar CA, Robison LL, Oeffinger KC. 
Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood 
Cancer Survivor Study. Cancer. 2005;103(8):1730-1739. 
19. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, 
Robison L. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the 
Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85(9):3227-3232. 
20. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, 
Nicholson HS, Yasui Y, Robison LL. Premature menopause in survivors of childhood cancer: a 
report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(13):890-896. 
21. Meacham LR, Sklar CA, Li S, Liu Q, Gimpel N, Yasui Y, Whitton JA, Stovall M, 
Robison LL, Oeffinger KC. Diabetes mellitus in long-term survivors of childhood cancer. 
Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. 
Arch Intern Med. 2009;169(15):1381-1388. 
22. Mostoufi-Moab S, Seidel K, Leisenring WM, Armstrong GT, Oeffinger KC, Stovall M, 
Meacham LR, Green DM, Weathers R, Ginsberg JP, Robison LL, Sklar CA. Endocrine 
Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer 
Survivor Study. J Clin Oncol. 2016;34(27):3240-3247. 
23. Chemaitilly W, Li Z, Huang S, Ness KK, Clark KL, Green DM, Barnes N, Armstrong 
GT, Krasin MJ, Srivastava DK, Pui CH, Merchant TE, Kun LE, Gajjar A, Hudson MM, Robison 
LL, Sklar CA. Anterior hypopituitarism in adult survivors of childhood cancers treated with 
cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol. 
2015;33(5):492-500. 
24. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, Green DM, 
Hammond S, Meadows AT, Mertens AC, Mulvihill JJ, Nathan PC, Neglia JP, Packer RJ, 
Rajaraman P, Sklar CA, Stovall M, Strong LC, Yasui Y, Zeltzer LK. The Childhood Cancer 
Survivor Study: a National Cancer Institute-supported resource for outcome and intervention 
research. J Clin Oncol. 2009;27(14):2308-2318. 
25. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. 
Conceptual framework and item selection. Med Care. 1992;30(6):473-483. 
26. Center for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance 
System Survey Questionnaire. http://www.cdc.gov/brfss/questionaires/pdf-ques/2003brfss.pdf. 
Accessed March 19, 2018. 
27. Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, 
Leisenring WM, Meacham LR, Mertens AC, Mulrooney DA, Oeffinger KC, Packer RJ, Robison 
LL, Sklar CA. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of 
published findings. J Clin Oncol. 2009;27(14):2339-2355. 
28. Recklitis CJ, Parsons SK, Shih MC, Mertens A, Robison LL, Zeltzer L. Factor structure 
of the brief symptom inventory--18 in adult survivors of childhood cancer: results from the 
childhood cancer survivor study. Psychological assessment. 2006;18(1):22-32. 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00627/5528895 by IU
PU
I U
niversity Library user on 06 August 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00627 
 
 
10 
29. Krull KR, Gioia G, Ness KK, Ellenberg L, Recklitis C, Leisenring W, Huang S, Stovall 
M, Robison LL, Zeltzer L. Reliability and validity of the Childhood Cancer Survivor Study 
Neurocognitive Questionnaire. Cancer. 2008;113(8):2188-2197. 
30. Krull KR, Annett RD, Pan Z, Ness KK, Nathan PC, Srivastava DK, Stovall M, Robison 
LL, Hudson MM. Neurocognitive functioning and health-related behaviours in adult survivors of 
childhood cancer: a report from the Childhood Cancer Survivor Study. Eur J Cancer. 
2011;47(9):1380-1388. 
31. Quinque EM, Villringer A, Kratzsch J, Karger S. Patient-reported outcomes in 
adequately treated hypothyroidism - insights from the German versions of ThyDQoL, ThySRQ 
and ThyTSQ. Health Qual Life Outcomes. 2013;11:68. 
32. Bianchi GP, Zaccheroni V, Solaroli E, Vescini F, Cerutti R, Zoli M, Marchesini G. 
Health-related quality of life in patients with thyroid disorders. Qual Life Res. 2004;13(1):45-54. 
33. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological 
well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled 
community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57(5):577-585. 
34. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, 
psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. 
Thyroid. 2007;17(3):249-258. 
35. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, 
Montori VM, Task Force ES. Testosterone therapy in men with androgen deficiency syndromes: 
an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-
2559. 
36. Kenney LB, Cohen LE, Shnorhavorian M, Metzger ML, Lockart B, Hijiya N, Duffey-
Lind E, Constine L, Green D, Meacham L. Male reproductive health after childhood, adolescent, 
and young adult cancers: a report from the Children's Oncology Group. J Clin Oncol. 
2012;30(27):3408-3416. 
37. Romerius P, Stahl O, Moell C, Relander T, Cavallin-Stahl E, Wiebe T, Giwercman YL, 
Giwercman A. Hypogonadism risk in men treated for childhood cancer. J Clin Endocrinol 
Metab. 2009;94(11):4180-4186. 
38. Aisenberg J, Hsieh K, Kalaitzoglou G, Whittam E, Heller G, Schneider R, Sklar C. Bone 
mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol. 
1998;20(3):241-245. 
39. Wasilewski-Masker K, Kaste SC, Hudson MM, Esiashvili N, Mattano LA, Meacham LR. 
Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines 
and review of the literature. Pediatrics. 2008;121(3):e705-713. 
40. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML, 
Stephens PA. Evaluation and treatment of adult growth hormone deficiency: an Endocrine 
Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006;91(5):1621-1634. 
41. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green 
DM, Armstrong GT, Nottage KA, Jones KE, Sklar CA, Srivastava DK, Robison LL. Clinical 
ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 
2013;309(22):2371-2381. 
42. Landier W, Armenian SH, Lee J, Thomas O, Wong FL, Francisco L, Herrera C, Kasper 
C, Wilson KD, Zomorodi M, Bhatia S. Yield of screening for long-term complications using the 
children's oncology group long-term follow-up guidelines. J Clin Oncol. 2012;30(35):4401-
4408. 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00627/5528895 by IU
PU
I U
niversity Library user on 06 August 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00627 
 
 
11 
Table 1: Demographic and treatment characteristics of adult survivors of childhood cancer with 
and without endocrine and metabolic disorders. 
Characteristics Total survivors (N=7,287) 
Survivors with and without endocrine and metabolic disorders 
With endocrine 
disorders, n (%) 
(N=4884) ** 
Without endocrine 
disorders, n (%) 
(N=2276) ** 
p value* 
Sex    <0.001 
Male 3566 (48.94%) 2504 (51.3%) 1011 (44.4%)  
Female 3721 (51.06%) 2380 (48.7%) 1265 (55.6%)  
Race    <0.001 
White, non-Hispanic 6586 (90.38%) 4386 (89.8%) 2086 (91.7%)  
Black, non-Hispanic 205 (2.81%) 134 (2.7%) 66 (2.9%)  
Hispanic 287 (3.94%) 226 (4.6%) 57 (2.5%)  
Other 209 (2.87%) 138 (2.8%) 67 (2.9%)  
Age at diagnosis (years)     
Mean ± SD 8 (2-14) 9 (3-15) 8 (2-14) <0.001 
Age at survey (years)     
Mean ± SD 32 (24-40) 33 (25-40) 31 (23-38) <0.001 
Interval between cancer diagnosis and 
assessment of endocrine function (years) 
    
Mean ± SD  24 (19-28) 24 (19-28) 23 (19-28) <0.001 
Diagnosis    <0.001 
    Leukemia 2506 (34.39%) 1765 (36.2%) 684 (30%)  
CNS tumors 896 (12.30%) 680 (14%) 203 (8.9%)  
Hodgkin lymphoma 952 (13.06%) 764 (15.6%) 183 (8.0%)  
Non-Hodgkin lymphoma 546 (7.49%) 369 (7.6%) 168 (7.4%)  
Wilms tumor 664 (9.11%) 296 (6.1%)  354 (15.6%)  
Neuroblastoma 469 (6.44%) 257 (5.3%) 199 (8.7%)  
    Soft tissue sarcoma 648 (8.89%) 419 (8.6%) 219 (9.6%)  
Ewing sarcoma 191 (2.62%) 116 (2.4%) 75 (3.3%)  
Osteosarcoma 390 (5.35%) 205 (4.2%) 180 (7.9%)  
Other 25 (0.34%) 13 (0.3%) 11 (0.5%)  
Health insurance    0.47 
Yes 6494 (89.82%) 4363 (90.0%) 2020 (89.5%)  
No 736 (10.18%) 484 (10.0%) 238 (10.5%)  
Employed    <0.001 
Yes 6391 (87.70%) 4215 (86.3%) 2095 (92.0%)  
No 896 (12.30%) 669 (13.7%) 181 (8.0%)  
Amputation    <0.001 
Yes  384 (5.27%) 200 (4.1%) 175 (7.7%)  
No 6903 (94.73%) 4684 (95.9%) 2101 (92.3%)  
Chemotherapy or radiation    <0.001 
No chemotherapy and no radiation 526 (7.68%) 285 (6.2%) 231 (10.9%)  
With Chemotherapy or radiation 6319 (92.32%) 4309 (93.8%) 1898 (89.1%)  
Any chemotherapy    0.004 
Yes  5362 (79.19%) 3549 (78.2%) 1711 (81.2%)  
No 1409 (20.81%) 992 (21.8%) 395 (18.8%)  
Alkylating agents    0.03 
Yes  3356 (49.56%) 2294 (50.5%) 1004 (47.7%)  
No 3415 (50.44%) 2247 (49.5%) 1102 (52.3%)  
Alkylating cumulative equivalent dose 
(mg/m2) 
   
0.005 
 mean±SD 9974(1782-18167) 10303(2066-18540) 9375(1214-17536)  
Steroids    <0.001 
Yes  3286 (48.53%) 2320 (51.1%) 901 (42.8%)  
No 3485 (51.47%) 2221 (48.9%) 1205 (57.2%)  
Stem-cell transplant     0.001 
Yes  295 (4.06%) 233 (4.8%) 59 (2.6%)  
No 6976 (95.94%) 4639 (95.2%) 2213 (97.4%)  
Any radiation therapy***     <0.001 
Yes  4480 (65.68%) 3318 (72.5%) 1089 (51.3%)  
No 2341 (34.32%) 1256 (27.5%) 1035 (48.7%)  
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   Brain radiation therapy    <0.001 
Yes  2301 (34.37%) 1834 (40.9%) 417 (20.2%)  
No 4394 (65.63%) 2654 (59.1%) 1668 (80.0%)  
Brain RT dose (cGy)    <0.001 
 mean±SD 3003(1527-4480) 3063(1569-4557) 2772(1380-4165)  
   Chest radiation therapy    <0.001 
Yes  1743 (26.05%) 1358 (30.3%) 374 (17.9%)  
No 4947 (73.95%) 3125 (69.7%) 1711 (82.1%)  
Chest RT dose(cGy)    <0.001 
 mean±SD 2945(1742-4148) 3032(1852-4212) 2643(1407-3879)  
  Abdominal or pelvic radiation therapy    <0.001 
Yes  1803 (26.95%) 1327 (29.6%) 452 (21.7%)  
No 4888 (73.05%) 3157 (70.4%) 1633 (78.3%)  
The maximum RT dose to Abdominal and 
pelvic(cGy) 
   
<0.001 
 mean±SD 2810(1616-4004) 2905(1712-4099) 2564(1429-3700)  
 Total body irradiation (TBI)    <0.001 
Yes  92 (1.38%) 79 (1.8%) 12 (0.6%)  
No 6596 (98.62%) 4402 (98.2%) 2073(99.4%)  
Grade 3-4 chronic health condition (other 
than endocrine)  
   
<0.001 
Yes 5433 (74.56%) 3808 (78.0%) 1536 (67.5%)  
No 1854 (25.44%) 1076 (22.0%) 740 (32.5%)  
Brief Symptom Inventory (BSI-18)    0.02 
Yes 600 (9.57%) 426 10.2%) 163 (8.3%)  
No 5668 (90.43%) 3771 (89.8%) 1804 (91.7%)  
Neuro-cognitive status (NCQ)     
Mean ± SD 54 (40-67) 54 (41-68) 52 (40-64) <0.001 
*Unknown value is not considered when calculating the p value except for household income. 
**There are 127 survivors with missing value of endocrine disorders. 
*** Childhood cancer survivors could belong to more than one radiation therapy category. 
Table 2: Proportion of adult survivors of childhood cancers with specific endocrine and 
metabolic disorders. 
Endocrine disorder    CTCAE Grade (version 4.03) Number (%) 
Hyperthyroidism              1     66 (0.91%) 
             2   139 (1.91%) 
Hypothyroidism              1   138 (1.89%) 
             2   792 (10.87%) 
Thyroid nodules              2   140 (1.92%) 
             3*   329 (4.51%) 
Thyroid cancer   Non-gradable     67 (0.9%) 
Short Stature   Non-gradable   821 (11.3%) 
Growth hormone deficiency              1   211 (2.90%) 
             2   353 (4.84%) 
Gonadal dysfunction (males): testicular failure              1     29 (0.81%) 
             2       1 (0.03%) 
             3      53 (1.49%) 
Gonadal dysfunction (females): ovarian failure              1        4 (0.11%) 
             3    247 (6.64%) 
Osteoporosis or osteopenia (low bone mineral density)              2    376 (5.16%) 
Diabetes mellitus              1        51 (0.70%) 
             2        63 (0.86%) 
             3        60 (0.82%) 
             4          1 (0.01%) 
Overweight/obesity    Non-gradable    3699 (50.7%) 
Other endocrine disorders              1     112 (1.54%) 
             3       19 (0.26%) 
* Grade 3 thyroid nodules are those that resulted in surgery leading to a sub-total or total thyroidectomy. 
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Table 3: Health related quality of life by type of endocrine/metabolic disorder among adult 
survivors of childhood cancers. 
SF-36 scale or 
component 
summary score 
Endocrine disorder (Reference group = survivors with no endocrine disorder) 
Any 
thyroid 
disorde
r 
Any 
growth 
disorde
rs 
Gonadal 
dysfunction 
(males) testicular 
failure  
Gonadal 
dysfunction 
(females) ovarian 
failure 
Osteo
poros
is 
Diab
etes 
Overw
eight/O
besity 
Other               
endocrine 
disorders not 
specified 
An
y 
end
ocr
ine 
dis
ord
er 
RR* 
(95% 
CI) 
RR 
(95% 
CI) 
RR (95% CI) RR (95% CI) 
RR 
(95% 
CI) 
RR 
(95% 
CI) 
RR 
(95% 
CI) 
RR (95% CI) 
RR 
(95
% 
CI) 
Physical 
function 
1.03 
(0.92-
1.15) 
1.14 
(0.99-
1.32) 
1.52 (1.10-2.10) 1.44 (1.18-1.76) 
1.29 
(1.12-
1.50) 
1.37 
(1.04-
1.79) 
1.20 
(1.04-
1.38) 
1.57 (1.19-2.06)       
 
1.2
5 
(1.0
5-
1.4
8)       
Role physical 
1.25 
(1.10-
1.43) 
0.96 
(0.82-
1.14) 
1.13 (0.67-1.92) 1.06 (0.84-1.36) 
1.41 
(1.20-
1.65) 
1.28 
(1.09-
1.50) 
1.00 
(0.89-
1.13) 
1.37 (1.00-1.87) 
1.0
9 
(0.9
5-
1.2
7) 
Bodily pain 
1.00 
(0.88-
1.14) 
0.79 
(0.68-
0.93) 
1.58 (1.20-2.09) 1.31 (1.06-1.62) 
1.37 
(1.18-
1.61) 
1.36 
(1.09-
1.70) 
1.28 
(1.15-
1.42) 
0.99 (0.71-1.38) 
1.2
7 
(1.1
2-
1.4
4) 
General health 
1.27 
(1.15-
1.40) 
0.98 
(0.87-
1.11) 
1.17 (0.80-1.71) 1.50 (1.32-1.70) 
1.45 
(1.30-
1.61) 
1.50 
(1.30-
1.72) 
1.26 
(1.15-
1.39) 
1.14 (0.91-1.43) 
1.4
9 
(1.3
2-
1.6
8) 
Vitality 
1.21 
(1.09-
1.35) 
0.95 
(0.83-
1.08) 
1.59 (1.13-2.25) 1.13 (0.94-1.36) 
1.20 
(1.04-
1.39) 
1.46 
(1.28-
1.68) 
1.19 
(1.08-
1.30) 
1.40 (1.15-1.71) 
1.2
1 
(1.0
9-
1.3
4) 
Role emotional 
1.21 
(1.06-
1.38) 
0.89 
(0.77-
1.04) 
1.57 (1.07-2.30) 1.06 (0.83-1.34) 
1.25 
(1.04-
1.49) 
0.93 
(0.66-
1.32) 
1.03 
(0.92-
1.15) 
1.04 (0.75-1.44) 
1.0
3 
(0.9
1-
1.1
7) 
Social function 
1.13 
(0.97-
1.32) 
0.84 
(0.70-
0.99) 
1.63 (1.21-2.20) 1.48 (1.17-1.87) 
1.19 
(0.96-
1.47) 
1.47 
(1.12-
1.92) 
1.03 
(0.90-
1.17) 
1.07 (0.75-1.52) 
1.0
7 
(0.9
2-
1.2
4) 
Mental health 
1.04 
(0.90-
1.19) 
0.87 
(0.75-
1.02) 
1.44 (1.08-1.91) 1.24 (0.99-1.56) 
1.28 
(1.06-
1.54) 
1.19 
(0.88-
1.60) 
1.05 
(0.94-
1.17) 
1.09 (0.80-1.47) 
1.0
9 
(0.9
6-
1.2
4) 
Physical 
component 
summary 
1.09 
(0.95-
1.24) 
0.99 
(0.83-
1.18) 
1.01 (0.55-1.85) 1.26 (1.08-1.46) 
1.45 
(1.29-
1.63) 
1.23 
(1.08-
1.40) 
1.25 
(1.12-
1.38) 
1.51 (1.15-1.99) 
 
1.3
0 
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(1.1
1-
1.5
2) 
Mental 
component 
summary 
1.16 
(1.01-
1.34) 
0.76 
(0.64-
0.90) 
1.67 (1.25-2.24) 1.04 (0.80-1.34) 
1.03 
(0.83-
1.29) 
0.99 
(0.70-
1.41) 
0.99 
(0.88-
1.10) 
1.07 (0.77-1.50) 
 
0.9
8 
(0.8
7-
1.1
1) 
Adjusted for sex, race, education, marital status, household income, health insurance, employment status, radiation 
yes/no, amputation, and other grade 3-4 chronic conditions.  
*Risk ratio. 
Table 4: Effect of number of endocrine and metabolic disorders on SF-36 subscales among adult 
survivors of childhood cancers. 
SF-36 scale or 
component 
summary 
score 
                                            Number of endocrine and metabolic disorders* 
1 vs. none 2 vs. none > 2 vs. none 2 vs. 1 >2 vs 1 >2 vs 2 
RR** (95%CI) RR (95% CI) RR (95%CI) RR (95%CI) RR (95%CI) RR (95%CI) 
Physical 
function 
1.2 (0.9-1.6) 1.6 (1.1-2.2) 1.8 (1.2-2.7) 1.3 (0.96-1.8) 1.4 (0.99-2.1) 1.1 (0.7-1.7) 
Role Physical 1.0 (0.8-1.2) 1.3 (1.1-1.6) 1.3 (0.99-1.6) 1.3 (1.1-1.6) 1.3 (1.03-1.6) 1.0 (0.8-1.2) 
Bodily pain 1.2 (1.1-1.4) 1.3 (1.1-1.5) 1.4 (1.2-1.8) 1.0 (0.9-1.2) 1.2 (0.9-1.4) 1.1 (0.9-1.4) 
General 
health 
1.3 (1.2-1.5) 1.7 (1.5-2.0) 2.0 (1.7-2.4) 1.3 (1.1-1.5) 1.5 (1.3-1.7) 1.1 (0.98-1.3) 
Vitality 1.1 (0.99-1.3) 1.4 (1.2-1.6) 1.6 (1.3-1.9) 1.2 (1.1-1.4) 1.4 (1.2-1.7) 1.2 (0.97-1.4) 
Role 
emotional 
1.0 (0.9-1.1) 1.1 (0.97-1.3) 1.2 (0.9-1.4) 1.2 (1.01-1.3) 1.2 (0.98-1.5) 1.0 (0.8-1.3) 
Social 
function 
1.0 (0.9-1.2) 1.1 (0.9-1.3) 1.3 (1.04-1.6) 1.0 (0.9-1.2) 1.3 (1.03-1.6) 1.2 (0.97-1.5) 
Mental health 1.1 (0.9-1.2) 1.1 (0.9-1.3) 1.3 (1.02-1.5) 1.0 (0.8-1.1) 1.2 (0.96-1.4) 1.2 (0.97-1.5) 
Physical 
component 
summary 
1.2 (0.9-1.5) 1.6 (1.3-2.1) 1.7 (1.3-2.4) 1.4 (1.1-1.8) 1.5 (1.1-2.0) 1.1 (0.8-1.4) 
Mental 
component 
summary 
1.0 (0.8-1.1) 1.0 (0.9-1.2) 1.0 (0.8-1.3) 1.1 (0.9-1.3) 1.0 (0.8-1.3) 1.0 (0.8-1.2) 
*Adjusted for sex, race, education, marital status, household income, health insurance, employment status, other 
grade 3-4 chronic condition, radiation yes/no, amputation, and task efficiency. The adjusted number of outcomes 
and percentages were calculated based on the survivors with endocrine information. 
**Risk ratio 
Table 5: Physical activity among adult survivors of childhood cancer and type of 
endocrine/metabolic disorder. 
Endocrine or metabolic disorder Value Recent participation in any organized physical activities. N (%) * 
Meets CDC guidelines for physical 
activity. N (%) * 
Thyroid disorders 
Yes 
(N=1247) 966 (77.5%)  653 (52.4%) 
No (N=6042)                   4738 (78.4%) 3382 (56.0%) 
RR** of Yes 
vs. No 1.02 (0.99-1.06) 1.04 (0.97-1.10) 
Growth Disorders 
Yes 
(N=1121)  798 (71.2%)  517 (46.1%) 
No (N=6118) 4867 (79.6%) 3489 (57.0%) 
RR of Yes vs. 
No 0.95 (0.91-0.99) 0.90 (0.83-0.97) 
Gonadal dysfunction (Males): 
testicular failure 
Yes (N=83)   59 (72.0%)   41 (50.6%) 
No (N=3485) 2775 (79.9%) 2114 (61.8%) 
RR of Yes vs. 0.93 (0.81-1.06) 0.96 (0.77-1.19) 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00627/5528895 by IU
PU
I U
niversity Library user on 06 August 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00627 
 
 
15 
No 
Gonadal dysfunction (females): 
ovarian failure 
Yes (N=251)   183 (72.9%)  106 (43.1%) 
No (N=3470) 2687 (77.7%)  1774 (51.8%) 
RR of Yes vs. 
No 0.95 (0.88-1.04) 0.88 (0.75-1.03) 
Osteoporosis 
Yes (N=376)  269 (71.5%)   164 (43.6%) 
No (N=6913) 5435 (78.6%) 3871 (56.0%) 
RR of Yes vs. 
No 0.94 (0.87-1.01) 0.87 (0.76-0.99) 
Diabetes 
Yes (N=175)  114 (65.1%)    72 (41.1%) 
No (N=7114) 5590 (78.6%) 3963 (55.7%) 
RR of Yes vs. 
No 0.84 (0.74-0.96) 0.82 (0.67-1.0008) 
Overweight/Obesity 
Yes 
(N=3699) 2834 (76.6%) 1969 (53.2%) 
No (N=3389) 2732 (80.6%) 1979 (58.4%) 
RR of Yes vs. 
No 0.97 (0.95-1.00) 0.92 (0.88-0.96) 
Other endocrine disorders 
Yes (N=131)  100 (76.3%)    56 (42.7%) 
No (N=7158) 5604 (78.3%) 3979 (55.6%) 
RR of Yes vs. 
No 1.02 (0.92-1.13) 0.82 (0.65-1.03) 
* Adjusted for sex, race, education, marital status, household income, health insurance, employment status, other 
grade 3-4 chronic condition, emotional health (BSI 18), radiation yes/no, amputation, and task efficiency. The 
adjusted number of outcomes and percentages were calculated based on the survivors with endocrine information. 
**Risk ratio 
Table 6: Effect of number of endocrine and metabolic disorders on physical activity among adult 
survivors of childhood cancer. 
Number of endocrine and 
metabolic disorders 
Value Recent participation in any organized physical activities. N (%) * 
Meets CDC guidelines for 
physical activity. N (%) * 
1 (N=3257) 2547 (78.2%) 1819 (55.8%) 
2 (N=1176)  887 (75.4%) 587 (49.9%) 
>2 (N=451)  309 (68.5%) 181 (40.1%) 
No endocrine/metabolic 
disorder (N=2278) 1868 (82.0%) 1385 (60.9%) 
 
                                                 RR**(95% CI) 
1 vs. No 
endocrine/metabolic 
disorder 
0.98 (0.96-1.005) 0.93 (0.89-0.98) 
2 vs. No 
endocrine/metabolic 
disorder 
0.96 (0.92-1.001) 0.91 (0.85-0.98) 
>2 vs. No 
endocrine/metabolic 
disorder 
                0.90 (0.83-0.97) 0.76 (0.67-0.85) 
2 vs. 1 0.98 (0.94-1.02) 0.98 (0.92-1.06) 
>2 vs. 1 0.92 (0.85-0.99) 0.82 (0.72-0.94) 
>2 vs. 2 0.93 (0.86-1.01) 0.84 (0.73-0.96) 
*Adjusted for sex, race, education, marital status, household income, health insurance, employment status, other 
grade 3-4 chronic condition, emotional health (BSI 18), radiation yes/no, amputation, and task efficiency. The 
adjusted number of outcomes and percentages were calculated based on the survivors with endocrine information. 
**Risk ratio 
Table 7: Adjusted risk-ratios of SF-36 outcomes between survivors with endocrine conditions 
reporting medication use for hormone replacement compared to those not on hormone 
replacement therapy. 
SF-36 scale or 
component 
summary score 
Survivors with hypothyroidism on 
replacement therapy at 2003 survey 
compared to survivors with no 
Males with gonadal dysfunction on 
testosterone therapy at 2003 survey 
compared to survivors with no 
Females with gonadal 
dysfunction on HRT at 2003 
survey compared to survivors 
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16 
replacement (N=110) * replacement (N=51) * with no replacement (N=168) * 
Physical function 1.00 (0.96-1.04) 0.19 (0.04-0.88) 0.90 (0.53-1.55) 
Role Physical 1.23 (0.61-2.50) 0.71 (0.71-2.53) 1.01 (0.57-1.80) 
Bodily pain 1.08 (0.64-1.81) 0.47 (0.15-1.50) 0.84 (0.55-1.26) 
General health 0.81 (0.50-1.32) 0.40 (0.14-1.19) 0.85 (0.62-1.15) 
Vitality 0.78 (0.50-1.22) 0.54 (0.25-1.18) 0.72 (0.48-1.09) 
Role emotional 0.74 (0.48-1.13) 0.38 (0.15-0.98) 1.02 (0.58-1.82) 
Social function 0.89 (0.46-1.69) 0.22 (0.05-0.97) 0.99 (0.71-1.38) 
Mental health 0.58 (0.36-0.93) 0.22 (0.06-0.86) 1.07 (0.65-1.77) 
Physical 
component 
summary 
0.77 (0.45-1.32) 0.16 (0.02-1.56) 1.09 (0.62-1.91) 
Mental 
component 
summary 
0.75 (0.41-1.36) 0.48 (0.16-1.43) 1.16 (0.62-2.20) 
*Adjusted for sex (only for testosterone therapy and HRT), race, education, marital status, household income, health 
insurance, employment status, radiation yes/no, amputation, and other grade 3-4 chronic condition.  
HRT: hormone replacement therapy 
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